Cadrenal Therapeutics Inc (CVKD) Quote

its trying to inch up now, lets ….

….

see what happens here.

DILUTE INTO NEWS

CVKD BIG NEWS

Green time run here, partnerships and approval coming in this order imo!

Earnings and possible announcements coming this week. Tick freaking tock...

Steady rise ahead imo

That’s my thought

This one checks all of the boxes and at this entry point, it should be a no brainer

IMO it’s time to buy!

That’s fair.

Tecarfarin will be brought to market. Question is, by who and when?

It looks settled and ready for reversal. On close watch so far

It’s going to move north again, imo!

CVKD new 52 lo

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Oh ok

DON'T OWN IT ANY LONGER

How about again?

CVKD....BEAUTIFUL PLAY...OUT AT 2 BUCKS BACK IN AT 1.10...LETS DO IT ALL OVER!!!

BEWARE OF THE CRIMINAL STOCK PROMOTER FROM NOVA SCOTIA, CANADA. THE SEC IS AFTER HIM FOR MULTIPLE SECURITIES VIOLATIONS!!!!!!!

CVKD IS JUST ONE OF MANY PUMP AND DUMPS THIS MAGGOT FRONT RUNS AND DUMPS ON SUCKERS!!!!!

The clown watch and learn

CVKD.. we have a sinker..

CVKD....BREAK OUT TO 2.00 COMING UP!

CVKD here she goes breaking 1.80

It’s a beast!

Trimmed half 1.80

CVKD 1.60 bid. Beast gap and run 0r gap and fill.

CVKD gaping hard and ready for 1.80

Looking good

CVKD...........................................https://stockcharts.com/h-sc/ui?s=CVKD&p=W&b=5&g=0&id=p86431144783

CVKD 1.80 trigger is next

Next week should be even better, imo

CVKD...BEAUTY CLOSE

CVKD...SETTING UP FOR A 2.00 RUN NEXT WEEK

10 days straight parabolic running,holy smokes!!! shorts better cover!!!!

CVKD...THE MONSTER HAS BEEN UNLEASHED

CVKD....MONSTER IN THE MAKING

CVKD gapping

Epic folks don’t wait, imo

CVKD...IN HERE...LIKE THIS SET UP!!

Real deal here. Don’t take my word do your DD.

Better DD this folks!

CVKD..............................https://stockcharts.com/h-sc/ui?s=CVKD&p=W&b=5&g=0&id=p86431144783

Excellent move up today!

Better get in

CVKD..................https://stockcharts.com/h-sc/ui?s=CVKD&p=W&b=5&g=0&id=p86431144783

hedges must be dumping into there fluffy pr

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(0.07) per share. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year.
Write to Benzinga at editorial@benzinga.com

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

https://finance.yahoo.com/news/cadrenal-therapeutics-provides-third-quarter-140000695.html

PONTE VEDRA, Fla., Nov. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

$CVKD FORM 8-K CURRENT REPORT

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001937993/000101376223005859/ea187126-8k_cadrenal.htm

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 20, 2023

Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082

(904) 300-0701
Ticker CVKD

On October 20, 2023, Cadrenal Therapeutics, Inc. (the “Company”), held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) where the Company’s stockholders voted on the following two (2) proposals and cast their votes as described below. These matters are described in detail in the Company’s definitive proxy statement as filed with the Securities and Exchange Commission on August 28, 2023 (the “Proxy Statement”).

As of August 25, 2023, the record date of the 2023 Annual Meeting, there were 13,022,754 issued and outstanding shares of common stock entitled to vote at the 2023 Annual Meeting. Present in person or by proxy at the 2023 Annual Meeting were more than thirty-four percent (34%) of the issued and outstanding capital stock entitled to vote at the 2023 Annual Meeting, which constituted a quorum.

The final voting results from the 2023 Annual Meeting for Proposals No. 1 and 2, as described in the Proxy Statement, is set forth below.

Proposal 1. Election of Directors.

The following two (2) individuals were elected as Class I directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes:
Quang Pham
Glynn Wilson

Proposal 2. Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023.

The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 based on the votes listed below:
Dated: October 23, 2023 CADRENAL THERAPEUTICS, INC. Quang Pham Chairman and Chief Executive Officer